Resverlogix Corp.
Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for patients with chronic illnesses. The company's lead drug is apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor for patients with cardiovascular disease, chronic kidney disease, type 2 diabetes mellitus, low high-density lipoprotein cholesterol, recent acute coronary sy… Read more
Resverlogix Corp. (RVXCF) - Net Assets
Latest net assets as of September 2025: $-88.89 Million USD
Based on the latest financial reports, Resverlogix Corp. (RVXCF) has net assets worth $-88.89 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.84 Million) and total liabilities ($96.74 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-88.89 Million |
| % of Total Assets | -1133.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 410.87 |
Resverlogix Corp. - Net Assets Trend (2001–2024)
This chart illustrates how Resverlogix Corp.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Resverlogix Corp. (2001–2024)
The table below shows the annual net assets of Resverlogix Corp. from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-81.73 Million | -9.75% |
| 2023-12-31 | $-74.47 Million | -25.63% |
| 2022-12-31 | $-59.28 Million | +0.98% |
| 2021-12-31 | $-59.87 Million | +6.62% |
| 2019-12-31 | $-64.11 Million | +69.14% |
| 2018-12-31 | $-207.72 Million | -148.24% |
| 2017-12-31 | $-83.68 Million | +17.62% |
| 2016-12-31 | $-101.57 Million | -79.99% |
| 2015-12-31 | $-56.43 Million | +23.46% |
| 2014-12-31 | $-73.73 Million | -16.63% |
| 2013-12-31 | $-63.22 Million | -114.26% |
| 2012-12-31 | $-29.50 Million | -1176.40% |
| 2011-12-31 | $2.74 Million | +168.47% |
| 2010-12-31 | $-4.00 Million | -189.68% |
| 2009-12-31 | $4.46 Million | -61.55% |
| 2008-12-31 | $11.61 Million | +113.35% |
| 2007-12-31 | $5.44 Million | +633.01% |
| 2006-12-31 | $-1.02 Million | -113.64% |
| 2005-12-31 | $7.48 Million | -24.01% |
| 2004-12-31 | $9.84 Million | +279.07% |
| 2003-12-31 | $2.60 Million | +175.63% |
| 2002-12-31 | $942.21K | +184.34% |
| 2001-12-31 | $331.37K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Resverlogix Corp.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 46987155171.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $334.62 Million | % |
| Other Components | $53.71 Million | % |
| Total Equity | $-81.73 Million | 100.00% |
Resverlogix Corp. Competitors by Market Cap
The table below lists competitors of Resverlogix Corp. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chiangmai Frozen Foods Public Company Limited
BK:CM
|
$6.08 Million |
|
Aquaron Acquisition Corp. Common Stock
NASDAQ:AQU
|
$6.08 Million |
|
Kurniamitra Duta Sentosa Tbk
JK:KMDS
|
$6.09 Million |
|
Odonate Inc.
PINK:ODTCD
|
$6.09 Million |
|
SANCY BERHAD
KLSE:03057
|
$6.08 Million |
|
POSaBIT Systems Corp
OTCQB:POSAF
|
$6.07 Million |
|
Viet Thang Corp
VN:TVT
|
$6.07 Million |
|
Hasen-Immobilien AG
STU:ABHA
|
$6.07 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Resverlogix Corp.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -74,474,000 to -81,735,000, a change of -7,261,000.
- Net loss of 7,635,000 reduced equity.
- Other factors increased equity by 374,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-7.63 Million | -9.34% |
| Other Changes | $374.00K | +0.46% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Resverlogix Corp.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | $0.10 | $0.03 | x |
| 2002-12-31 | $0.09 | $0.03 | x |
| 2003-12-31 | $0.16 | $0.03 | x |
| 2004-12-31 | $0.48 | $0.03 | x |
| 2005-12-31 | $0.31 | $0.03 | x |
| 2006-12-31 | $-0.04 | $0.03 | x |
| 2007-12-31 | $0.21 | $0.03 | x |
| 2008-12-31 | $0.39 | $0.03 | x |
| 2009-12-31 | $0.11 | $0.03 | x |
| 2010-12-31 | $-0.08 | $0.03 | x |
| 2011-12-31 | $0.04 | $0.03 | x |
| 2012-12-31 | $-0.40 | $0.03 | x |
| 2013-12-31 | $-0.80 | $0.03 | x |
| 2014-12-31 | $-0.87 | $0.03 | x |
| 2015-12-31 | $-0.56 | $0.03 | x |
| 2016-12-31 | $-0.96 | $0.03 | x |
| 2017-12-31 | $-0.61 | $0.03 | x |
| 2018-12-31 | $-1.10 | $0.03 | x |
| 2019-12-31 | $-0.29 | $0.03 | x |
| 2021-12-31 | $-0.25 | $0.03 | x |
| 2022-12-31 | $-0.23 | $0.03 | x |
| 2023-12-31 | $-0.27 | $0.03 | x |
| 2024-12-31 | $-0.30 | $0.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Resverlogix Corp. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-38.37%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | -56.52% | -3173.53% | 0.02x | 1.09x | $-220.43K |
| 2002 | -54.43% | 0.00% | 0.00x | 1.15x | $-607.05K |
| 2003 | -54.33% | -8020.21% | 0.01x | 1.04x | $-1.67 Million |
| 2004 | -28.82% | -1620.79% | 0.02x | 1.04x | $-3.82 Million |
| 2005 | -85.33% | -2620.11% | 0.03x | 1.08x | $-7.13 Million |
| 2006 | 0.00% | -5707.10% | 0.02x | 0.00x | $-16.45 Million |
| 2007 | -516.95% | 0.00% | 0.00x | 3.81x | $-28.67 Million |
| 2008 | -155.95% | -13101.81% | 0.01x | 1.63x | $-19.26 Million |
| 2009 | -615.35% | -979685.04% | 0.00x | 1.89x | $-27.91 Million |
| 2010 | 0.00% | 2512.19% | 0.01x | 0.00x | $2.48 Million |
| 2011 | 685.22% | 0.00% | 0.00x | 4.51x | $18.51 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $46.31 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-48.78 Million |
| 2014 | 0.00% | 0.00% | 0.00x | 0.00x | $-10.95 Million |
| 2015 | 0.00% | 0.00% | 0.00x | 0.00x | $-14.07 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-36.05 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-49.94 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-142.03 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $124.44 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-18.78 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $2.32 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.29 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $538.50K |
Industry Comparison
This section compares Resverlogix Corp.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Resverlogix Corp. (RVXCF) | $-88.89 Million | -56.52% | N/A | $6.08 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |